Jae-Young Ha
Senior Vice President AriBio
Jae Young Ha is a senior biopharmaceutical executive at AriBio with over 40 years of experience in the global development and registration of prescription medicines. He holds a Master’s degree in Drug Analysis from the College of Pharmacy at Seoul National University and has built an extensive international career across leading biotech and pharmaceutical organisations. His previous roles include CEO at Oxbridge Pharma Ltd., Vice President at Mavena AG, Director at Swiss Red Cross (ZLB), and Director at Novartis AG, where he contributed to drug development, regulatory strategy, and global market access. Leveraging this deep expertise, he plays a key role in advancing AriBio’s therapeutic pipeline in Alzheimer’s Disease and strengthening its innovative position in the international CNS landscape.
Seminars
- Demonstrating how AR1001 induces multiple neuroprotective effects, with potential to be disease-modifying
- Investigating the commercial and clinical variability of AR1001 under POLARIS-AD (global Phase III trial)
- Showing how AR1001 achieves simultaneous multimodal effects while maintaining an exceptional safety profile
- Outlining the first example of a Korean CNS asset out-licensed at Phase III vs.typical earlier-stage licensing deals
- Demonstrating how Korean biopharma can retain and elevate their clinical assets to maximize financial returns
- Innovative collaboration models in the biopharma industry between Korea and China
